DEVELOPMENT OF EARLY STAGES OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH OBESITY
- Autores: Gallyamov MG1, Severova MM1, Surkova OA1
-
Afiliações:
- Edição: Nº 6 (2010)
- Páginas: 66-68
- Seção: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245979
- ID: 245979
Citar
Texto integral
Resumo
Aim. Study of role of obesity in development of early stages of chronic kidney disease.
Methods. 93 patients (mean age 42,9±11,3 years) with body mass index (BMI) ≥25,0 kg/m2 (mean BMI 34,3±6,7 kg/m2) were included into the study. In all patients standard clinical and laboratory parameters were evaluated, serum C-peptide and leptin levels were determined. Albuminuria was assessed, glomerular filtration rate (eGFR) was estimated according to MDRD formula.
Results. In 32,7% hyperinsulinemia was detected, diabetes mellitus type 2 - in 11,8%, impaired glucose tolerance - in 21,5%, arterial hypertension - in 80,6%. In 52,7% patients chronic kidney disease (CKD) was diagnosed (eGFR 79±21 ml/min/1,73m2, albuminuria 61,6±81,0 mg/24 hours). 20,4% had CKD I stage, 63,3% - CKD II stage, 16,3% - CKD III stage. According to the CKD stage, there were significant differences in serum level of leptin, C-peptide, Sokoloff-Lyon index. Serum leptin level, uricaemia and mean blood pressure were main factors, associated with eGFR fall in patients with obesity.
Conclusion. Obesity may play a causative role in development of early stages of chronic kidney disease.
Methods. 93 patients (mean age 42,9±11,3 years) with body mass index (BMI) ≥25,0 kg/m2 (mean BMI 34,3±6,7 kg/m2) were included into the study. In all patients standard clinical and laboratory parameters were evaluated, serum C-peptide and leptin levels were determined. Albuminuria was assessed, glomerular filtration rate (eGFR) was estimated according to MDRD formula.
Results. In 32,7% hyperinsulinemia was detected, diabetes mellitus type 2 - in 11,8%, impaired glucose tolerance - in 21,5%, arterial hypertension - in 80,6%. In 52,7% patients chronic kidney disease (CKD) was diagnosed (eGFR 79±21 ml/min/1,73m2, albuminuria 61,6±81,0 mg/24 hours). 20,4% had CKD I stage, 63,3% - CKD II stage, 16,3% - CKD III stage. According to the CKD stage, there were significant differences in serum level of leptin, C-peptide, Sokoloff-Lyon index. Serum leptin level, uricaemia and mean blood pressure were main factors, associated with eGFR fall in patients with obesity.
Conclusion. Obesity may play a causative role in development of early stages of chronic kidney disease.
Palavras-chave
Bibliografia
- Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004.
- Сагинова Е.А., Галлямов М.Г., Северова М.M. Современные представления о поражении почек при ожирении. Клиническая нефрология, 2010, 2: 66 - 71
- Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, Gaziano JM. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005; 46(5):871-880
- Ikee R, Hamasaki Y, Oka M, Maesato K, Mano T, Moriya H, Ohtake T, Kobayashi S. Glucose metabolism, insulin resistance, and renal pathology in non-diabetic chronic kidney disease. Nephron Clin Pract. 2008; 108(2): c163-с168.
- Комитет экспертов ВНОК - НОНР. Основные положения проекта рекомендаций Всероссийского научного общества кардиологов и Научного общества нефрологов России по оценке функционального состояния почек у больных сердечно-сосудистыми заболеваниями или с повышенным риском их развития. Кардиоваскулярная терапия и профилактика. 2008; 4: 8-20.
- Комитет экспертов ВНОК. Проект рекомендаций экспертов Всероссийского Научного Общества Кардиологов по диагностике и лечению метаболического синдрома. М., 2009.
- Мухин Н.А. Снижение скорости клубочковой фильтрации - общепопуляционный маркер неблагоприятного прогноза. Тер архив, 2007; 6: 5-10
- Мухин Н.А., Арутюнов Г.П., Фомин В.В. Альбуминурия - маркер поражения почек и риска сердечно-сосудистых осложнений. Клиническая нефрология, 2009, 1: с. 5-10.
- Российское Медицинское Общество по Артериальной Гипертонии - Всероссийское Научное Общество Кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008.